From the Guidelines
Cosentyx (secukinumab) does not typically cause leukocytosis as a common side effect. Leukocytosis, which is an elevated white blood cell count, is not listed among the frequent adverse reactions associated with this medication. Cosentyx is an interleukin-17A inhibitor primarily used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis by targeting specific inflammatory pathways. The most common side effects of Cosentyx include upper respiratory infections, nasopharyngitis, diarrhea, and injection site reactions [ 1 ]. In fact, because Cosentyx suppresses certain immune functions, it's more often associated with potential increased risk of infections rather than stimulation of white blood cell production [ 1 ]. If a patient taking Cosentyx develops leukocytosis, it would be important to investigate other causes such as infection, inflammation, stress, or other medications, as this would not be an expected direct effect of the medication itself.
Some key points to consider when prescribing Cosentyx include:
- Monitoring patients for signs of infection, as Cosentyx may increase the risk of infections [ 1 ]
- Considering anti-tuberculosis therapy before starting Cosentyx in patients with latent TB [ 1 ]
- Regular blood monitoring during Cosentyx treatment is advisable, but specifically watching for leukocytosis is not a primary concern with this medication
- Cosentyx has been shown to be effective in treating various forms of psoriasis, including moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [ 1 ]
Overall, the current evidence suggests that Cosentyx is a safe and effective treatment option for various inflammatory conditions, and leukocytosis is not a common side effect associated with this medication [ 1 ].
From the Research
Cosentyx and Leukocytosis
- There is no direct evidence in the provided studies that Cosentyx (secukinumab) causes leukocytosis.
- The studies primarily focus on the efficacy and safety of secukinumab in treating psoriatic arthritis, psoriasis, and ankylosing spondylitis, with no mention of leukocytosis as a side effect 2, 3, 4, 5, 6.
- The studies do report on the safety profile of secukinumab, including adverse events and laboratory abnormalities, but leukocytosis is not specifically mentioned 3, 4, 5, 6.
- One study reports on the risk of malignancy in patients treated with secukinumab, but does not mention leukocytosis as a potential risk factor 3.
- Overall, the available evidence does not suggest a link between Cosentyx and leukocytosis, but it is essential to consult the official prescribing information and discuss any concerns with a healthcare professional.